RDTs - Does the FDA accept RDTs as a pivotal trial? There are good reasons that the FDA should NOT accept such a trial - i.e. if the treatment has moderate mortality (e.g. 5%), only works in a small fraction of the population (e.g. 20%) and then has only moderate efficacy (e.g. HR=0.70).
I guess this is another way of saying that part of any ph ii RDT had better be an exhaustive search for a biomarker. Either that or some way to prove that in the group for whom it is not efficacious that there are no excess deaths in the treated population.
Market Data 
Markets 
AI
